Semaglutide
Semaglutide $80.00$185.00
Back to products
Retatrutide
Retatrutide $105.00$250.00

Tirzepatide

$105.00$250.00

Tirzepatide is a synthetic dual-hormone receptor agonist that targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Marketed under the brand name Mounjaro (for diabetes) and Zepbound (for weight loss), it’s a once-weekly injectable designed to manage type 2 diabetes and obesity with impressive efficacy, surpassing many existing treatments.

SKU: N/A Category:
Description

Description

Primary Uses of Tirzepatide

  1. Type 2 Diabetes Management:
    • Approved by the FDA in May 2022 as Mounjaro, tirzepatide significantly lowers HbA1c (average blood sugar levels) and improves insulin sensitivity.
    • In the SURPASS trials, it reduced HbA1c by up to 2.3% (at 15 mg) over 40-52 weeks, outperforming insulin and GLP-1-only drugs like semaglutide in head-to-head comparisons.
  2. Weight Loss (Obesity Treatment):
    • Approved as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities (e.g., hypertension, diabetes).
    • The SURMOUNT trials showed average weight loss of 20.9% (about 48 lbs) at 15 mg after 72 weeks—rivaling bariatric surgery outcomes and exceeding semaglutide’s 14-15%.
  3. Cardiometabolic Benefits:
    • Reduces triglycerides, LDL cholesterol, and blood pressure, while improving overall metabolic health, potentially lowering cardiovascular risk (ongoing trials like SURPASS-CVOT will confirm this).
  4. Potential for Fatty Liver Disease:
    • Early data suggests it reduces liver fat, making it a candidate for metabolic dysfunction-associated steatotic liver disease (MASLD), though it’s not yet approved for this use.

How It Works

  • Dual Action:
    • GLP-1: Suppresses appetite, slows gastric emptying, and boosts insulin release in a glucose-dependent manner.
    • GIP: Enhances insulin secretion, promotes fat metabolism, and may improve energy expenditure, complementing GLP-1’s effects.
  • This synergy leads to better blood sugar control and more significant weight loss than GLP-1 agonists alone (e.g., Ozempic).

How It’s Used

  • Administration: Subcutaneous injection once weekly, typically in the abdomen, thigh, or upper arm, using a pre-filled pen.
  • Dosage: Starts at 2.5 mg for 4 weeks (to reduce side effects), then escalates to 5 mg, 10 mg, or 15 mg, depending on response and tolerance. Max dose is 15 mg/week.

Product Usage: This item is designed exclusively for use as a research chemical in laboratory settings and in vitro experiments, to be handled only by licensed, trained professionals. It is not intended or approved for human or animal consumption. Any misuse, misbranding, or mislabeling as a drug, food, or cosmetic is strictly forbidden. All accompanying information is provided solely for educational purposes.

Additional information

Additional information

Milligram

5mg

,

10mg

,

15mg